Steroid usage in clinical practice
PDF
Cite
Share
Request
Review
P: 73-84
August 2021

Steroid usage in clinical practice

J Turk Soc Rheumatol 2021;13(2):73-84
1. Özel Medical Park Uşak Hastanesi, İç Hastalıkları Kliniği, Uşak, Türkiye
No information available.
No information available
Received Date: 09.07.2019
Accepted Date: 03.02.2020
Publish Date: 31.08.2021
PDF
Cite
Share
Request

ABSTRACT

The synthesis site of steroids is zona fasciculata layer of the adrenal cortex. Today, the expression of corticosteroid, an important treatment option in many diseases, reflects both glucocorticoid and mineralocorticoid. Glucocorticoids are physiologically synthesized as cortisol 10-20 mg per day and contain a little mineralocorticoid activity. They bind to receptors in peripheral cell cytoplasms and are transferred to the nucleus and exert their effects. Apart from replacement therapy in adrenal insufficiency, exogenous administration to the body has various clinical effects due to its mineralocorticoid properties. Therefore, by modifying the chemical structure of synthetic synthesized derivatives for medicinal purposes, glucocorticoid effects were strengthened by reducing mineralocorticoid effects. The success of treatment in synthetic glucocorticoids of various forms is determined by the type, dosage, route of administration, duration of the usage and the mixed effect which it provides on various body functions. The statement of “Double-edged sword” is associated with the natural physiological effects of molecular, cellular and organ-based side effects. Therefore, the effects of the drug, the necessity and the form of usage should be explained in detail to the patients at the beginning of the treatment. Patients should be advised about diet, social habits, and exercise and awareness should be raised about the mutual side effect monitoring after the basic clinical evaluation of the physician. The rationale for the use of steroids, despite all the incredible scientific advances in modern medical technology, can be summarized as “in the right place, as much as necessary and as few as possible”.

References

1
Cannon GW. Kortikosteroidler dahil immunsupresif ilaçlar. İçinde: Goldman L, Schafer AI, editors. Cecil Medicine. 24. Basım. Ankara: Güneş Tıp Kitabevi; 2015:159-61. 
2
Cain DW, Cidlowski JA. Specificity and sensitivity of glucocorticoid signaling in health and disease. Best Pract Res Clin Endocrinol Metab 2015;29:545-56.
3
Glyn J. The discovery and early use of cortisone. J R Soc Med 1998;91:513-7.
4
Aral Y. Adrenal korteks hastalıklarına giriş. İçinde: İlicin G, Biberoglu K, Suleymanlar G, Unal S, editors. İç Hastalıkları. 3. Baskı. Ankara: Güneş Tıp Kitabevi; 2012; 2028-50.
5
Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
6
Williams DM. Clinical pharmacology of corticosteroids. Respir Care 2018;63:655-70.
7
Aydın G, Ata AM. Romatolojide glukokortikoidler. İçinde: Ataman S, Bodur H, editors. Romatoloji e-Kitap. Ankara: Turkish League Against Rheumatism; 2019:1-25.
8
Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol 2017;237:171-96.
9
Cruz-Topete D, Cidlowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation 2015;22:20-32.
10
Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How glucocorticoids affect the neutrophil life. Int J Mol Sci 2018;19:4090.
11
Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
12
Desmet SJ, De Bosscher K. Glucocorticoid receptors: finding the middle ground. J Clin Invest 2017;127:1136-45.
13
Chirumamilla CS, Palagani A, Kamaraj B, et al. Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads. Front Immunol 2017;8:1324.
14
Krasselt M, Baerwald C. Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther 2016;10:1047-58.
15
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and Biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
16
Buttgereit F, Da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
17
Safy M, de Hair MJH, Jacobs JWG, Buttgereit F, Kraan MC, van Laar JM. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One 2017;12:e0188810. doi: 10.1371/journal.pone.0188810.
18
Camellino D, Dejaco C. Update on treatment of polymyalgia rheumatica. Reumatismo 2018;70:59-66.
19
Postolova A, Chen JK, Chung L. Corticosteroids in myositis and scleroderma. Rheum Dis Clin North Am 2016;2:103.
20
Van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects. Arthritis Res Ther 2014;16(Suppl 2):S2.
21
Pufall MA. Glucocorticoids and cancer. Adv Exp Med Biol 2015;872:315-33.
22
Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci 201718:2201.
23
Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016;42:157-76, ix-x.
24
den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012;64:639-46.
25
Liu D, Ahmet A, Ward L,  et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
26
Yue C, Wei R, Liu Y. Perioperative systemic steroid for rapid recovery in total knee and hip arthroplasty: a systematic review and meta-analysis of randomized trials. J Orthop Surg Res 2017;12:100.
27
Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am 2017;43:489-502.
28
Hwang JL, Roy E. Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014;30:96-102.
29
Suh S, Park MK. Glucocorticoid-ınduced diabetes mellitus: an ımportant but overlooked problem. Endocrinol Metab 2017;32:180-9.
30
Cayakar A, Küçük IG. İç Hastalıkları penceresinden kalp ve akciğer nakline bakış. İç Hastalıkları Dergisi 2018;25:99-122.
31
Clore JN, Thurby-Hay L. Glucocorticoid-induced hypergly­cemia. Endocr Pract 2009;15:469-74.
32
Grossman E, Messerli FH. Hipertansiyon. Braunwald’ın Kalp Hastalıkları Ek Kitabı. İçinde: Black HR, Elliott WJ, editors. Ankara: Güneş Tıp Kitabevi; 2009:144-9.
33
Liu C,  Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J Cardiac Fail 2014;20:625-9.
34
Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007;46:1102-6.
35
Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ 2012;345:e4928.
36
van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
37
Zhang Q, L V J, Jin L. Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J Int Med Res 2018;46:2141-8.
38
Kasifoglu T. İnflamatuar kas hastalığı. İçinde: Sayarlıoğlu M, editor. ROVAG Romatoloji Vaka Derlemeleri-I. İstanbul: Türkiye Romatoloji Derneği; 2010:109-16.
39
Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
40
No authors listed. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-47.
41
Sutter SA, Stein EM. The skeletal effects of ınhaled glucocorticoids. Curr Osteoporos Rep 2016;14:106-13.
42
Gibbison, López-López JA, Higgins JP, et al. Corticosteroids in septic shock: a systematic review and network meta-analysis Critical Care 2017;21:78.
43
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on Prevention and treatment of hepatitis B virus reactivation during immunsupressive drug therapy. Gastroenterology 2015;148:221-44.
44
Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 2017;76:1-9.
45
Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72:1905-13.